© 2020 MJH Life Sciences™ and Diagnostic Imaging. All rights reserved.
Yamanouchi to develop ImaRx agent
September 2, 1998
Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which
Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which ImaRx is co-developing in the U.S. with Du Pont Pharmaceutical under the name DMP115.